Global attention-deficit/hyperactivity disorder (ADHD) is one of the most common and most studied neurodevelopmental disorders in children, and teens, and continues into adulthood. According to the World Health Organization (WHO), ADHD affects around 5% of children and 2.5% of adults. It’s affected on paying attention and controlling behavior. It is marked by an ongoing pattern of inattention or hyperactivity-impulsivity that interferes with functioning or development. Inattention means a person may have difficulty in staying on task, sustaining focus, and staying focused. Hyperactivity means a person seems to move about constantly, including in situations when it is not appropriate. Impulsivity means a person may act without thinking or have difficulty with self-control. Attention deficit disorder (ADD) is the old name for attention-deficit/hyperactivity disorder (ADHD). It was officially changed in the 1990s. The causes of attention-deficit/hyperactivity disorder (ADHD) are not sure but there are some genes that tend to run attention-deficit/hyperactivity disorder (ADHD) in families. Brain chemicals may be out of balance in people with this disease also the area of the brain that controls attention is less active in children with attention-deficit/hyperactivity disorder (ADHD). Some risk factors may play a role in the development of ADHD, some of them are poor nutrition, smoking, drinking, in child’s being born prematurely, brain injury or brain disorder, damage to the front of the brain, called the frontal lobe, can cause problem in controlling impulse and emotions. It can be hard to diagnose attention-deficit/hyperactivity disorder (ADHD), especially in children and teens. Doctors use the American Psychiatric Association’s guidelines, which are based on how many symptoms a person has and how they had them.
While the exact reasons for the increase in ADHD diagnoses are not entirely clear, some experts suggest that it may be due to a combination of factors. Simply more awareness and understanding of attention-deficit/hyperactivity disorder (ADHD) among healthcare providers and the general public, will lead to more diagnoses. Changes in diagnostic criteria over time may have contributed to the increases in reported cases.
Global Attention-Deficit Hyperactivity Disorder (ADHD) – Competitive Landscape
Parallel Learning, a telepsychiatry service for children, raises USD 20 million from investors including Tiger Global and Oblivious Ventures. MindTension has raised a total of USD 2 million for its tool helping diagnose and treat optimization of ADHD and related mental health comorbidities. The key sponsors type in the ADHD market are institutions, company, and government among them company sponsors dominates the market.
Some Key of the Key Players in the Global Attention-Deficit/Hyperactivity Disorder (ADHD) Include –
Global Attention-Deficit Hyperactivity Disorder (ADHD) – Growth Drivers
The prevalence of persistent adult Global Attention-Deficit/Hyperactivity Disorder (ADHD) and symptomatic adult both decreased with advancing age, the prevalence of persistent adult ADHD was 2.58% and that of symptomatic adult ADHD was 6.76%, translating to 139.84 million and 366.33 million of affected adults. The FDA has approved the Monarch external Trigeminal Nerve Stimulation (SNS) system for children 7 to 12 who aren’t taking ADHD medications. The most recent developments in Global Attention-Deficit/Hyperactivity Disorder (ADHD) research is the development of new therapies that better address the needs of individuals living with the condition. Several newer stimulant formulations with potential advantages over traditional options have emerged and gained regulatory approval. Compared with traditional care, the start-up models are reportingly using cost-cutting methods, such as favoring quick assessment and a low-cost workforce. Due to telehealth and remote prescription of controlled substances, it become easier than ever to get diagnosed with and treated for ADHD online.
Global Attention-Deficit Hyperactivity Disorder (ADHD) – Restraints
Attention-deficit hyperactivity disorder in children and adolescents is associated with a substantial economic burden that is largely driven by education costs, followed by direct healthcare costs, followed by direct healthcare costs and caregiver costs. According to the National Center for Biotechnology Information (NCBI), The total annual societal excess costs associated with ADHD were estimated at USD 19.4 billion among children and USD 13.8 billion in adolescents, and healthcare costs in children about USD 5.0 billion and USD 4.0 billion in adolescents. Inadequate knowledge regarding the symptoms, treatments, and consequences of untreated ADHD and fear of overdiagnosis and misdiagnosis. Access to specialist services in some regions is limited.
Global Attention-Deficit Hyperactivity Disorder (ADHD) – Opportunities
New therapies such as attention deficit hyperactivity disorder better address the needs of individuals living with the condition. The development of digital health tools and apps for tracking and managing ADHD symptoms offers significant opportunities. Personalized medicine and genetic testing can offer opportunities to tailor ADHD treatments. Increasing awareness of the ADHD market expands the services and medications in different regions. Organizations involved in research and clinical trials related to ADHD treatments can benefit from increased funding and collaboration opportunities.
Global Attention-Deficit Hyperactivity Disorder (ADHD) – Geographical Insight
The market of global attention deficit hyperactivity disorder is segmented into the regions North America, Latin America, Europe, Middle East & Africa. North America is the largest market for ADHD due to the well recognition, diagnosis, and treatment of the disease, also there’s a strong focus on research, and various medication and non-pharmacological treatments are widely available. In Europe, countries like the UK, Germany, and France have high attention deficit hyperactivity disorder (ADHD) awareness and access to diagnosis treatment. In Asia-Pacific, countries like Japan, South Korea, and China in which growing awareness and diagnosis but access to treatment can be limited in rural areas. In regions like the Middle East and Africa diagnosis and awareness are limited but recognition of mental health issues is increasing.
Global Attention-Deficit Hyperactivity Disorder (ADHD) – Key Development
We can customize every report – free of charge – including purchasing stand-alone sections or country-level reports
We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail
Cognizance market research is continuously guiding customers around the globe towards strategies for transformational growth. Today, businesses have to innovate more than ever before, not just to survive, but to succeed in the future
© 2023 All rights Reserved. Cognizance Market Research
